Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas

BACKGROUND: Targeting the epigenome of cancerous diseases represents an innovative approach, and the DNA methylation inhibitor decitabine is recommended for the treatment of hematological malignancies. Although epigenetic alterations are also common to solid tumors, the therapeutic efficacy of decit...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Zijiao, Liu, Lu, Borlak, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199547/
https://www.ncbi.nlm.nih.gov/pubmed/37208732
http://dx.doi.org/10.1186/s13148-023-01500-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199547/
https://www.ncbi.nlm.nih.gov/pubmed/37208732
http://dx.doi.org/10.1186/s13148-023-01500-1

Ejemplares similares